文献速递白血病

LSD1与mTORC1联合抑制在MLL易位急性髓系白血病中的临床前活性

Pre-clinical activity of combined LSD1 and mTORC1 inhibition in MLL-translocated acute myeloid leukaemia.
PubMed 文献 · Leukemia · 2019-11-28

该临床前研究通过全基因组CRISPR-Cas9筛选发现mTORC1信号组分是LSD1抑制的增敏靶点。在细胞系和原代细胞中,抑制mTORC1联合LSD1抑制可增强分化并减少克隆形成,尤其在MLL易位AML中,提示该联合方案可进入早期临床试验。

要点

  • mTORC1组分敲低或药物抑制可增敏LSD1抑制。
  • 联合抑制增强MLL易位AML细胞分化并减少克隆形成。
  • 该联合方案是MLL易位AML的候选分化治疗策略。

核心结论

  • 双重抑制mTORC1和LSD1是增强MLL易位AML分化的候选联合策略,可考虑早期临床试验评估。

研究设计与样本

  • 临床前研究,采用全基因组CRISPR-Cas9 dropout筛选,并在细胞系和原代细胞中体外及体内验证。

主要发现

  • 筛选鉴定出mTORC1氨基酸感应臂的多个组分RRAGA、MLST8、WDR24和LAMTOR2为LSD1抑制的细胞增敏因子。
  • 敲低mTORC1组分或药物抑制mTORC1联合LSD1抑制,在体外和体内细胞系及原代细胞中增强分化。
  • 该联合在模拟微小残留病背景下大幅降低原代人类AML细胞的克隆形成频率。
  • 观察到与终末单核细胞谱系分化相关的转录因子基因协同上调。

临床怎么用

  • 对于MLL易位AML,可考虑将mTORC1抑制剂与LSD1抑制剂联合作为促分化治疗策略进行早期临床试验。

局限性

  • 研究为临床前阶段,尚未在患者中评估安全性和疗效。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The histone demethylase lysine-specific demethylase 1 (LSD1 or KDM1A) has emerged as a candidate therapeutic target in acute myeloid leukaemia (AML); tranylcypromine-derivative inhibitors induce loss of clonogenic activity and promote differentiation, in particular in the MLL-translocated molecular subtype of AML. In AML, the use of drugs in combination often delivers superior clinical activity. To identify genes and cellular pathways that collaborate with LSD1 to maintain the leukaemic phenotype, and which could be targeted by combination therapies, we performed a genome-wide CRISPR-Cas9 dropout screen. We identified multiple components of the amino acid sensing arm of mTORC1 signalling-RRAGA, MLST8, WDR24 and LAMTOR2-as cellular sensitizers to LSD1 inhibition. Knockdown of mTORC1 components, or mTORC1 pharmacologic inhibition, in combination with LSD1 inhibition enhanced differentiation in both cell line and primary cell settings, in vitro and in vivo, and substantially reduced the frequency of clonogenic primary human AML cells in a modelled minimal residual disease setting. Synergistic upregulation of a set of transcription factor genes associated with terminal monocytic lineage differentiation was observed. Thus, dual mTORC1 and LSD1 inhibition represents a candidate combination approach for enhanced differentiation in MLL-translocated AML which could be evaluated in early phase clinical trials.

来源:Leukemia,查看原文。版权归原作者所有。

引用

  1. Deb G, Wingelhofer B, Amaral FMR, et al. Pre-clinical activity of combined LSD1 and mTORC1 inhibition in MLL-translocated acute myeloid leukaemia. Leukemia. 2019. PMID: 31780813. doi:10.1038/s41375-019-0659-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。